Do Rheumatologists Treat Fibromyalgia?

Rheumatologists do treat fibromyalgia, and many patients receive their initial diagnosis from one. But the relationship between the specialty and the condition is complicated. A national survey of Canadian rheumatologists found that half endorsed potentially refusing consultations with fibromyalgia patients, and only about 42 percent agreed that effective therapies even exist for the syndrome. That tension between expertise and reluctance shapes the experience of millions of people trying to get help.

Why Rheumatologists Are Involved in the First Place

Fibromyalgia produces widespread musculoskeletal pain, fatigue, and cognitive difficulty. Those symptoms overlap heavily with autoimmune and inflammatory conditions like rheumatoid arthritis, lupus, polymyalgia rheumatica, and ankylosing spondylitis. When a patient shows up at a primary care office with body-wide pain and exhaustion, the first clinical question is often whether something inflammatory or autoimmune is going on. That question lands squarely in rheumatology’s territory.

A rheumatologist’s core contribution to fibromyalgia care is differential diagnosis: confirming that the symptoms are not caused by a systemic or rheumatic disease. A physical exam, patient history, and targeted lab work can rule out those conditions, and multiple evidence-based guidelines from Canada, Germany, and Israel have agreed that specialist referral is only needed when another physical or mental illness is reasonably suspected.¹ Once those possibilities are excluded and the symptom pattern fits fibromyalgia, the diagnosis can technically be made by any clinician. But in practice, many patients and primary care providers still look to rheumatologists for confirmation.

A 2025 patient-oriented guideline put it plainly, recommending that patients see a physician, preferably a rheumatologist or pain specialist, and that early diagnosis and treatment are important.² So the field’s own guidelines still point patients toward rheumatology as a starting point, even as many rheumatologists themselves resist taking on the ongoing care.

Why Many Rheumatologists Are Reluctant

The Canadian survey that found half of rheumatologists would potentially refuse fibromyalgia consultations also revealed something striking about treatment attitudes. Consistent with national guidelines, most respondents managed fibromyalgia with education, exercise therapy, antidepressants, and non-narcotic analgesics when they did see these patients. But fewer than half believed any of those approaches actually worked, with endorsement of individual therapies ranging from just 9 to 47 percent.³ Imagine prescribing treatments you don’t believe in for a condition whose very existence some of your colleagues question. That frustration drives a lot of the reluctance.

Rheumatology training emphasizes conditions with clear inflammatory or autoimmune markers. Fibromyalgia has neither. There are no blood tests that confirm it and no imaging findings that point to it. The dominant scientific view is that fibromyalgia reflects altered pain processing in the central nervous system, a concept researchers now call nociplastic pain.⁴ Studies using psychophysical testing support this framework, finding that fibromyalgia resembles a nociplastic pain condition tied to complex sensitization processes involving pain, psychological, and sensory variables in interconnected clusters.⁵ That kind of central nervous system pain processing sits outside the traditional wheelhouse of joint and autoimmune disease, which makes some rheumatologists feel they are the wrong specialists for the job.

There is also a practical concern. Rheumatology has a workforce shortage in many countries, with long wait times for appointments. One study found that lower-priority patients referred to a rheumatology clinic waited an average of about 184 days for their consultation, and the no-show rate for those appointments exceeded institutional targets, likely driven in part by those long waits.⁶ Rheumatologists who feel their limited appointment slots should go to patients with inflammatory arthritis or vasculitis may view fibromyalgia referrals as a misuse of scarce resources.

What Happens in Primary Care

In most health systems, the bulk of fibromyalgia management falls to primary care physicians. A survey of U.S. primary care providers found that they personally treated roughly two-thirds of their fibromyalgia patients rather than referring them out. But confidence was a problem: about 46 percent reported some uncertainty when diagnosing the condition.⁷ A separate, broader physician survey found that over half of all doctors reported difficulty diagnosing fibromyalgia, and about 54 percent felt their training on the condition was inadequate. Rheumatologists reported the least difficulty and greatest confidence, while primary care physicians and psychiatrists reported the most.⁸

This creates an odd dynamic. The specialists best equipped to diagnose fibromyalgia often don’t want to manage it long-term, while the generalists who end up managing it often don’t feel equipped to diagnose it confidently. Patients get caught in the middle.

The Referral Maze

Qualitative research has documented what this looks like from the patient’s perspective. In one study analyzing online patient communities, fibromyalgia was most commonly diagnosed by neurologists or rheumatologists. But nearly half of the posts in discussion threads about finding a doctor were requests for referrals, with patients sharing physician names, addresses, and notes about each doctor’s expertise, treatment methods, and bedside manner across different regions and countries.⁹ That level of crowdsourced referral networking signals how difficult it is to find a provider who takes fibromyalgia seriously.

Patients have also reported being dismissed, stigmatized, or not taken seriously at healthcare visits. Those negative experiences led to personal hardships including delays in diagnosis and high healthcare utilization, as patients bounced between providers looking for someone who would listen.¹⁰ The diagnostic delay is a real problem. Without a clear biomarker, the diagnosis depends on a clinician who knows the condition well enough to recognize it and is willing to commit to the label.

How Fibromyalgia Is Treated Once Diagnosed

Whether a rheumatologist or a primary care doctor manages the condition, the treatment approach looks broadly similar. International guidelines show strong agreement on a few core strategies, though they sometimes weigh individual treatments differently. The American Pain Society, the Canadian Pain Society, the German AWMF, and the European League Against Rheumatism (EULAR) all included systematic reviews as their highest level of evidence. Three of the four gave their highest recommendation to aerobic exercise, cognitive-behavioral therapy, amitriptyline, and multicomponent treatment. The most recent EULAR guideline, notably, elevated exercise to its top recommendation, shifting away from the pharmacotherapy emphasis of its earlier version.¹¹

An international Delphi consensus built on these guidelines, recommending aerobic exercise, patient education, sleep hygiene, and cognitive-behavioral therapy as core treatments for all fibromyalgia symptoms. Mind-body exercises were recommended as core interventions for pain, fatigue, and sleep problems, while mindfulness was voted a core treatment specifically for depression.¹²

On the medication side, three drugs have FDA approval specifically for fibromyalgia in the United States: pregabalin, duloxetine, and milnacipran. But real-world prescribing often deviates from label recommendations. An analysis of prescribing patterns found that about 35 percent of patients receiving pregabalin started at a dose lower than recommended, and only 27 percent reached recommended maintenance dosing. Duloxetine and milnacipran fared better, with 91 and 80 percent of patients reaching recommended maintenance doses, respectively.¹³ Adherence is another challenge. A large U.S. claims analysis found that only about 31 percent of newly diagnosed fibromyalgia patients even started a guideline-recommended medication, and with the exception of duloxetine, discontinuation rates at six months exceeded 50 percent for all agents studied.¹⁴

Those numbers help explain rheumatologists’ skepticism. When many patients stop their medications within months, and those who stay on them often receive subtherapeutic doses, it becomes hard to evaluate whether the treatments are genuinely failing or just not being used as intended.

When Fibromyalgia Overlaps with Rheumatic Disease

One scenario where rheumatologists can’t avoid fibromyalgia is when it coexists with an autoimmune condition they’re already treating. This happens more than you might expect. A study at a tertiary hospital found that 15 percent of patients with seropositive rheumatoid arthritis also met diagnostic criteria for fibromyalgia. Among those patients, pregabalin was the most commonly prescribed fibromyalgia medication, used by about 70 percent. But most received lower-than-recommended doses, and discontinuation rates were high across all medications: about 29 percent of those on pregabalin, 42 percent on duloxetine, and 35 percent on amitriptyline stopped their medications, primarily due to side effects or lack of effectiveness.¹⁵

This overlap is clinically tricky. A patient with rheumatoid arthritis whose pain doesn’t improve despite good inflammatory control may have unrecognized fibromyalgia amplifying their symptoms. If the rheumatologist escalates RA medications instead of addressing the central pain processing component, the patient gets more drug exposure without benefit. Recognizing fibromyalgia as a concurrent condition is a meaningful part of good rheumatologic care, even for practitioners who wouldn’t voluntarily take on pure fibromyalgia patients.

Gender Bias and Diagnostic Assumptions

Fibromyalgia is diagnosed far more often in women than in men, and researchers have raised serious questions about how much of that imbalance reflects genuine prevalence versus diagnostic bias. The two key distortions are selection bias and confirmation bias. Physicians are more likely to think of and diagnose fibromyalgia in women than in men, an observation supported by findings such as the composition of a large national databank where 95.3 percent of the 1,761 patients referred with fibromyalgia were women.¹⁶

What this means practically: if you’re a man with widespread pain and fatigue, a rheumatologist may be less likely to consider fibromyalgia and more likely to continue searching for an inflammatory cause. That could lead to a longer diagnostic journey and unnecessary testing. Conversely, women presenting with pain may be labeled with fibromyalgia more quickly than is warranted, potentially missing other diagnoses. The bias cuts both ways, and it’s something both patients and clinicians should be aware of.

The Small Fiber Neuropathy Question

One area of active research could eventually change how rheumatologists think about fibromyalgia. A study found objective evidence that some patients with chronic pain labeled as fibromyalgia actually have small-fiber polyneuropathy, a distinct condition that can be tested for with skin biopsy and sometimes treated directly.¹⁷ Small-fiber neuropathy involves damage to the thin nerve fibers in skin and organs that carry pain and temperature signals. Unlike fibromyalgia, it has a detectable physical finding and, in some cases, an identifiable and treatable cause like diabetes or an autoimmune process.

This doesn’t mean most fibromyalgia patients actually have small-fiber neuropathy. But it suggests that the current diagnostic category may be too broad, lumping together patients with different underlying mechanisms under one umbrella. If future research can reliably identify subgroups, it could give rheumatologists and neurologists clearer targets for treatment rather than the current approach of managing symptoms without a specific mechanism to address.

The Case for Multidisciplinary Programs

Because no single treatment works well for most fibromyalgia patients, the evidence increasingly points toward combining approaches. Systematic reviews of multidisciplinary rehabilitation for fibromyalgia found that the most effective programs incorporated patient education alongside a comprehensive exercise component including aerobic exercise, stretching, strengthening, and relaxation, often combined with cognitive-behavioral therapy for self-management skills.¹⁸ A pilot randomized trial of a community-based multidisciplinary group intervention found improvements in perceived quality of care, daily functioning, depressive symptoms, and pain beliefs, with no adverse events reported.¹⁹

These programs typically involve physical therapists, psychologists, occupational therapists, and a coordinating physician. The coordinating physician might be a rheumatologist, a pain specialist, a physiatrist, or a primary care doctor. The model matters more than the specific specialty leading it. A well-structured multidisciplinary program run by a primary care team may serve fibromyalgia patients better than a rheumatologist working alone with a prescription pad.

Disability Claims and the Medicolegal Role

Rheumatologists sometimes get pulled into fibromyalgia care through a side door: disability paperwork. Because fibromyalgia has no lab tests or imaging findings, adjudicating disability claims related to it is challenging. The process depends heavily on validated functional assessments, and the available tests for symptom validity are of uncertain value in identifying exaggeration.²⁰ Patients often need documentation from a specialist to support their claims, which brings them to a rheumatologist even when their ongoing treatment is managed elsewhere. Some rheumatologists are willing to perform this evaluation even when they prefer not to take on long-term fibromyalgia management.

Digital Tools and Remote Care

Given the access barriers and long wait times that characterize rheumatology care, digital health tools are gaining interest for fibromyalgia management. Mobile apps and online programs can provide symptom tracking, pain diary features, educational resources, and cognitive-behavioral interventions to support pain self-management.²¹ These tools don’t replace a physician visit, but they can fill gaps between appointments and support the self-management strategies that guidelines recommend as frontline treatment.

Telemedicine also opens the possibility of consulting with a rheumatologist or pain specialist without the months-long wait that in-person visits often require. For a condition where the physical exam is focused on tender points and symptom history rather than joint swelling or imaging, virtual consultations can be a reasonable fit. Whether a patient ultimately needs hands-on rheumatology care or just a specialist’s confirmation of diagnosis, the barrier to access may be lower than it was a decade ago.